Novo Nordisk A/s

Novo Nordisk Healthcare Ag

Jens Buchardt

Henrik Sune Andersen

Carsten Behrens

Nils Langeland Johansen

Kristian Kjaergaard

Soeren Padkjaer

Susanne Nedergaard Grell

Birgitte Friedrichsen

Henning Ralf Stennicke

Peder Lisby Noerby

Mette Dahl Andersen

Dorrit Baunsgaard

Lars Hornum

Katarina Haakansson

Jesper Kastrup

Albrecht Gruhler

Leif Noerskov-Lauritsen

Jens Jacob Hansen

Leif Norskov-Lauritsen

Magali A Zundel

Leif NØRSKOV-Lauritsen

Jing Su

Henrik ØStergaard

Eva H Norling Olsen

Thomas R Barnett

Tony Pusateri

The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

Antagonistic DR3 ligands

The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.

Growth hormones with prolonged in-vivo efficacy

The present invention relates to modified therapeutic proteins, such as e.g. coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules such as e.g. FVII, FVIII, or FIX comprising a hydrophobic side group.

Conjugated proteins

The present invention relates to conjugated Factor VIII variants. The present invention in particular relates to conjugated FVIII variants comprising different polymeric groups as well as use thereof.

Conjugated FVIII variants

The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.

The present invention relates generally to a novel method of introducing property modifying groups to a protein. In particular, the present invention relates to the derivatization of lysine residues, as well as new conjugates of growth hormones with improved pharmacological properties, and methods for their preparation and use in therapy.

Method for selectively modifying a protein via transglutaminase catalyzed reaction

Growing community of inventors

Gentofte, Denmark

Jens Buchardt